Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 676 to 690 of 1688 results for carers

  1. Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment ID 6467

    Awaiting development [GID-TA11585] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant ID 6468

    Awaiting development [GID-TA11581] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker ID 6469

    Awaiting development [GID-TA11575] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment ID 6463

    Awaiting development [GID-TA11590] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over ID6457

    Awaiting development [GID-TA11576] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors TSID 12064

    Awaiting development [GID-TA11594] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG TSID 12042

    Awaiting development [GID-TA11592] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over TSID 12036

    Awaiting development [GID-TA11596] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Troriluzole for spinocerebellar ataxia ID 6456

    Awaiting development [GID-TA11549] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over ID 6475

    Awaiting development [GID-TA11586] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer ID6399

    Awaiting development [GID-TA11499] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Resminostat for maintenance treatment of advanced mycosis fungoides or Sézary syndrome ID6478

    Awaiting development [GID-TA11606] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Dupilumab for treating bullous pemphigoid [ID6479]

    Awaiting development [GID-TA11615] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer ID6490

    Awaiting development [GID-TA11624] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Lenacapavir for HIV pre-exposure prophylaxis in people 16 years and over at risk of infection [ID6495]

    Awaiting development [GID-TA11638] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development